Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Eloxx Pharmaceuticals Inc | ELOX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.82 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.82 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 3.54 - 10.90 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 3.82 | USD |
Eloxx Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.51M | 3.14M | - | 0 | -36.07M | -11.47 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Eloxx Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ELOX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 7.54 | 10.90 | 3.54 | 8.18 | 660,192 | -3.72 | -49.34% |
| 3 Years | 95.20 | 101.20 | 1.6959 | 39.08 | 597,889 | -91.38 | -95.99% |
| 5 Years | 452.00 | 538.40 | 1.6959 | 63.17 | 389,783 | -448.18 | -99.15% |
Eloxx Pharmaceuticals Description
| Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel ribonucleic acid (RNA)-modulating drug candidates that are formulated to treat rare and ultra-rare premature stop codon diseases. The ELX-02, the company's lead investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins. The ELX-02, is in the early stages of clinical development for systemic administration for cystic fibrosis and cystinosis. |
